Skip to main content
Local News

Bioprocess Development and Tissue Engineering of Stem Cells to Study Heart Disease

By August 23, 2022No Comments

Human pluripotent stem cells (hPSCs) harbour enormous potential for regenerative medicine and offer a unique opportunity to advance the development of cell-based therapies. The development of hPSC biobanks, and use of hPSCs in clinical trials, drug screening, and disease modeling, all demand robust stem cell manufacturing and expansion. Although the hPSC manufacturing field is evolving rapidly, a bottleneck is throttling clinical application: existing technologies cannot efficiently scale up production of clinically viable stem cells.

In collaboration with bioengineers at the University of Calgary and with the support from Stem Cell Network of Canada (SCN), Drs. Michael Kallos, Derrick Rancourt, Breanna Borys, and Leili Rohani (a postdoctoral research scientist in Dr. Zachary Laksman’s lab at the HLI) developed a system for bioprocess bioengineering and cell manufacturing of human pluripotent stem cells in a bioreactor to produce clinically viable hPSCs.